Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis

AIMS: Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients. METHODS AND RESULTS: This prespecified analysis from ODYSSEY OUTCOMES compared the effect of alirocumab vs. placebo in 18 924 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinnaeve, Peter R, Schwartz, Gregory G, Wojdyla, Daniel M, Alings, Marco, Bhatt, Deepak L, Bittner, Vera A, Chiang, Chern-En, Correa Flores, Roger M, Diaz, Rafael, Dorobantu, Maria, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Pordy, Robert, Roe, Matthew T, Sy, Rody G, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Steg, Ph Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308542/
https://www.ncbi.nlm.nih.gov/pubmed/31732742
http://dx.doi.org/10.1093/eurheartj/ehz809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308542/
https://www.ncbi.nlm.nih.gov/pubmed/31732742
http://dx.doi.org/10.1093/eurheartj/ehz809

Ejemplares similares